PTC Therapeutics, Inc.
Substituted reverse pyrimidine Bmi-1 inhibitors

Last updated:

Abstract:

Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Status:
Grant
Type:

Utility

Filling date:

26 Sep 2019

Issue date:

23 Nov 2021